




## Section: 6. Anti-infective medicines

ATC codes: J01EB03

Indication	Bacterial infection of unspecified site <span style="float: right;">ICD11 code: <b>1C81</b></span>
INN	Sulfadimidine
Medicine type	Biological agent
Antibiotic groups	<span style="border: 1px solid black; padding: 2px;">A ACCESS</span>
List type	Core
Formulations	Oral > Liquid: 500 mg per 5 mL Oral > Solid: 500 mg Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Removed in 1997 ( <a href="#">TRS 882</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Sulfadimidine</a> 
DrugBank	<a href="#">Sulfadimidine (Sulfamethazine)</a> 

## Summary of evidence and Expert Committee recommendations

Sulfadimidine was replaced by sulfadiazine since this drug has been shown to be more effective for the treatment of toxoplasmosis when used in combination with pyrimethamine. Attention is drawn to the lower solubility of sulfadiazine compared to sulfadimidine and the need to ensure adequate hydration of the patient during its use.

